CN113195537A - 抗体文库及方法 - Google Patents

抗体文库及方法 Download PDF

Info

Publication number
CN113195537A
CN113195537A CN201980081249.0A CN201980081249A CN113195537A CN 113195537 A CN113195537 A CN 113195537A CN 201980081249 A CN201980081249 A CN 201980081249A CN 113195537 A CN113195537 A CN 113195537A
Authority
CN
China
Prior art keywords
antibody
variant
amino acid
dna
xaa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980081249.0A
Other languages
English (en)
Chinese (zh)
Inventor
R·别克
C·斯科特
D·麦卡恩
L·麦克吉尔
H·摩根
N·坎贝尔
J·麦克洛里
A·奥凯恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fusion Antibody Public Ltd
Original Assignee
Fusion Antibody Public Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1817188.4A external-priority patent/GB201817188D0/en
Priority claimed from GBGB1904754.7A external-priority patent/GB201904754D0/en
Priority claimed from GBGB1905032.7A external-priority patent/GB201905032D0/en
Application filed by Fusion Antibody Public Ltd filed Critical Fusion Antibody Public Ltd
Publication of CN113195537A publication Critical patent/CN113195537A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1089—Design, preparation, screening or analysis of libraries using computer algorithms
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B10/00—Directed molecular evolution of macromolecules, e.g. RNA, DNA or proteins
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201980081249.0A 2018-10-22 2019-10-22 抗体文库及方法 Pending CN113195537A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1817188.4 2018-10-22
GBGB1817188.4A GB201817188D0 (en) 2018-10-22 2018-10-22 Antibody library
GB1904754.7 2019-04-04
GBGB1904754.7A GB201904754D0 (en) 2019-04-04 2019-04-04 Antibody library and method
GBGB1905032.7A GB201905032D0 (en) 2019-04-09 2019-04-09 Antibody library and method
GB1905032.7 2019-04-09
PCT/GB2019/053010 WO2020084298A1 (en) 2018-10-22 2019-10-22 Antibody library and method

Publications (1)

Publication Number Publication Date
CN113195537A true CN113195537A (zh) 2021-07-30

Family

ID=68393020

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980081249.0A Pending CN113195537A (zh) 2018-10-22 2019-10-22 抗体文库及方法

Country Status (10)

Country Link
US (2) US12378696B2 (cg-RX-API-DMAC7.html)
EP (1) EP3870607A1 (cg-RX-API-DMAC7.html)
JP (2) JP7853096B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210084509A (cg-RX-API-DMAC7.html)
CN (1) CN113195537A (cg-RX-API-DMAC7.html)
AU (1) AU2019365135B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021007529A2 (cg-RX-API-DMAC7.html)
CA (1) CA3115150A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021004149A (cg-RX-API-DMAC7.html)
WO (1) WO2020084298A1 (cg-RX-API-DMAC7.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114775065A (zh) * 2022-04-22 2022-07-22 武汉华美生物工程有限公司 一种半合成纳米抗体库构建方法和纳米抗体库
CN115171774A (zh) * 2022-05-17 2022-10-11 慧壹科技(上海)有限公司 一种抗体/大分子药物的亲和力改造系统和方法
CN117736329A (zh) * 2023-12-25 2024-03-22 华润生物医药有限公司 抗pd-1抗体及其用途
WO2026067631A1 (zh) * 2024-09-26 2026-04-02 上海循曜生物科技有限公司 增强FIX和FIXa活性的纳米抗体

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7473339B2 (ja) * 2017-03-07 2024-04-23 エフ. ホフマン-ラ ロシュ アーゲー 代替の抗原特異的抗体変異体を発見するための方法
CN112289369B (zh) * 2020-12-15 2021-04-02 武汉华美生物工程有限公司 一种基于深度学习的抗体库构建方法及装置

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073346A1 (en) * 1999-05-27 2000-12-07 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Immunoconjugates having high binding affinity
US20180127510A1 (en) * 2015-05-22 2018-05-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies fragments inhibiting both the cath-d catalytic activity and its binding to the lrp1 receptor
CN109576292A (zh) * 2018-12-21 2019-04-05 深圳市爱思迪生物科技有限公司 一种抗体文库的构建方法及其应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073346A1 (en) * 1999-05-27 2000-12-07 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Immunoconjugates having high binding affinity
US20180127510A1 (en) * 2015-05-22 2018-05-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies fragments inhibiting both the cath-d catalytic activity and its binding to the lrp1 receptor
CN109576292A (zh) * 2018-12-21 2019-04-05 深圳市爱思迪生物科技有限公司 一种抗体文库的构建方法及其应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRUNO H. MULLER 等: ""In Vitro Affinity Maturation of an Anti-PSA Antibody for Prostate Cancer Diagnostic Assay"", 《JOURNAL OF MOLECULAR BIOLOGY》, vol. 414, pages 1 - 5 *
JENNY BOSTROM 等: ""Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site"", 《SCIENCE》, vol. 323, no. 5921, pages 1610, XP002560553, DOI: 10.1126/science.1165480 *
YU-CHENG SU 等: ""Mimicking the germinal center reaction in hybridoma cells to isolate temperature-selective anti-PEG antibodies"", 《MABS》, vol. 6, no. 4, pages 1070 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114775065A (zh) * 2022-04-22 2022-07-22 武汉华美生物工程有限公司 一种半合成纳米抗体库构建方法和纳米抗体库
CN115171774A (zh) * 2022-05-17 2022-10-11 慧壹科技(上海)有限公司 一种抗体/大分子药物的亲和力改造系统和方法
CN117736329A (zh) * 2023-12-25 2024-03-22 华润生物医药有限公司 抗pd-1抗体及其用途
CN117736329B (zh) * 2023-12-25 2024-11-12 华润生物医药有限公司 抗pd-1抗体及其用途
WO2026067631A1 (zh) * 2024-09-26 2026-04-02 上海循曜生物科技有限公司 增强FIX和FIXa活性的纳米抗体

Also Published As

Publication number Publication date
WO2020084298A1 (en) 2020-04-30
US12378696B2 (en) 2025-08-05
JP2022512650A (ja) 2022-02-07
US20210388063A1 (en) 2021-12-16
KR20210084509A (ko) 2021-07-07
BR112021007529A2 (pt) 2021-08-03
JP7853096B2 (ja) 2026-04-28
AU2019365135A1 (en) 2021-05-13
JP2026016427A (ja) 2026-02-03
US20250382726A1 (en) 2025-12-18
AU2019365135B2 (en) 2026-08-13
MX2021004149A (es) 2021-06-15
EP3870607A1 (en) 2021-09-01
CA3115150A1 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
JP7853096B2 (ja) 抗体ライブラリー及び方法
Traxlmayr et al. Construction of a stability landscape of the CH3 domain of human IgG1 by combining directed evolution with high throughput sequencing
CA2572917C (en) Look-through mutagenesis for developing altered polypeptides with enhanced properties
Yazaki et al. Mammalian expression and hollow fiber bioreactor production of recombinant anti-CEA diabody and minibody for clinical applications
AU2017428737B2 (en) Dynamic human heavy chain antibody libraries
WO2003074679A2 (en) Antibody optimization
KR101763345B1 (ko) 단백질 조합 기반의 Fv 라이브러리 및 이의 제조 방법
KR20190025980A (ko) 항-pcsk9 단일클론 항체
WO2011160429A1 (zh) 抗p185(her2/erbb2)人源化抗体
US20110313134A1 (en) Engineered antibodies with reduced immunogenicity and methods of making
CN104769113A (zh) 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用
CN116888149A (zh) 含异二聚体抗体Fc的蛋白以及其制备方法
JP5850846B2 (ja) 繊維状ファージ上でのジスルフィド結合二量体タンパク質の提示
KR102216032B1 (ko) 합성 항체 라이브러리의 생성 방법, 상기 라이브러리 및 그 적용(들)
Weidenhaupt et al. Functional mapping of conserved, surface‐exposed charges of antibody variable domains
EP2560992A2 (en) Binding domains
US20110245100A1 (en) Generation of antibodies to an epitope of interest
CN114245804A (zh) 修饰的人可变域
KR20220026869A (ko) 신규 항체 라이브러리 제조방법 및 이로부터 제조된 라이브러리
TW202532437A (zh) Cfc1結合分子
CN119855835A (zh) 基于共同轻链产生双特异性抗体的方法
HK40051447A (en) Screening and engineering method of super-stable immunoglobulin variable domains and their uses
KR20220087488A (ko) Pd-l1 결합 분자
WO2009150426A2 (en) Method

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination